Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Equipment
  3. switzerland
  4. cell therapies
Show results for
Products
Services
Training
Applications

Companies


Refine by
Locations
Back to All Locations

  • Europe
  • Switzerland
Brands

  • gain
  • aurealis therapeutics
  • gain morquio b
  • seraccess

Cell Therapies Equipment Supplied In Switzerland

5 equipment items found
In SwitzerlandAvailable In SwitzerlandNear Switzerland

Aurealis Therapeutics - Model AUP-16 - Four-in-One Cell Therapy System

Aurealis Therapeutics - Model AUP-16 - Four-in-One Cell Therapy System

by:Aurealis Therapeutics   based inBasel, SWITZERLAND
Our new approach to chronic wound healing moves far beyond symptom ...
CONTACT SUPPLIER

Gain MORQUIO B - Model Type IV - Mucopolysaccharidosis Disease

Gain MORQUIO B - Model Type IV - Mucopolysaccharidosis Disease

by:Gain Therapeutics, Inc.   based inBethesda, MARYLAND (USA)
These mutations result in the misfolding and subsequent dysfunction of GLB, which leads to the toxic substrate accumulation of keratan sulfate in organs and tissues. Very limited and investigational symptomatic treatment options include substrate reduction therapy, enzyme replacement therapy, bone marrow transplantation, stem cell transplantation ...
CONTACT SUPPLIER

Gain - Mucopolysaccharidosis Type 1 (Mps 1)

Gain - Mucopolysaccharidosis Type 1 (Mps 1)

by:Gain Therapeutics, Inc.   based inBethesda, MARYLAND (USA)
These mutations cause the misfolding and dysfunction of IDUA, which leads to the toxic buildup of large sugars in the bone, cartilage, cornea, heart and central nervous system (CNS). There is currently no cure for these patients; however, enzyme replacement therapy and hematopoietic stem cell transplant are used to manage the non-CNS symptoms. Gain is developing ...
CONTACT SUPPLIER

Gain - Model GM1 - Gangliosidosis Disease

Gain - Model GM1 - Gangliosidosis Disease

by:Gain Therapeutics, Inc.   based inBethesda, MARYLAND (USA)
These mutations result in the misfolding and subsequent dysfunction of GLB, which leads to the toxic substrate accumulation of GM1 ganglioside in organs and tissues. Very limited and investigational symptomatic treatment options include substrate reduction therapy, enzyme replacement therapy, bone marrow transplantation, stem cell transplantation ...
CONTACT SUPPLIER

Seraccess - Model SENSE - Unrivalled Artificial Pancreas for Unmanageable Diabetes

Seraccess - Model SENSE - Unrivalled Artificial Pancreas for Unmanageable Diabetes

by:Securecell AG   based inUrdorf, SWITZERLAND
Seraccess® was forged from Securecell’s expertise in automating and digitalizing the biotechnology space. Our immense knowledge of connecting expansive bioprocessing systems, microfluidics and documenting processes down to the molecular level led us to solutions that could greatly impact the Artificial Pancreas Device System (APDS) market for a significantly underserved diabetes ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT